patent.fyi
Applications  /  US 2026/0355189
United States Patent Application Publication

US 2026/0355189 A1

Published
Nov 12, 2026
Filed
Sep 21, 2023
Earliest date on the face
Sep 22, 2022
Classification
A61K 31/502
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.3Ether at the X position

What ifWhat if X were an ether oxygen bonded directly to a phenyl group?
Claim language“X is —NRX(R2) or C1-C6-alkyl”

The core and phenyl group form a core–O–phenyl linkage with two carbon–oxygen single bonds. The oxygen serves as a hydrogen-bond acceptor and provides a bent connection between the two groups.

1.4Phenyl substituent on nitrogen

What ifWhat if RX were a phenyl group bonded directly to the nitrogen of X?
Claim language“RX is H or C1-C6-alkyl”

The nitrogen bonds to the phenyl group through an aromatic carbon and retains its bonds to the core and R2. Conjugation between the nitrogen lone pair and the phenyl ring reduces the lone pair's availability for protonation.

1.7Oxygen in a six-membered ring

What ifWhat if the group at the Cy position were a saturated six-membered ring containing one oxygen atom?
Claim language“carbocyclic ring system”

A tetrahydropyran-4-yl group attaches through the ring carbon opposite the oxygen. The chair conformation gives the group a three-dimensional shape, and the ring oxygen serves as a hydrogen-bond acceptor.

1.11Four-membered ring around nitrogen

What ifWhat if R and R′ joined the bound nitrogen in a four-membered azetidine ring?
Claim language“5- to 8-membered heterocycloalkyl”

Three methylene groups and the bound nitrogen form the saturated ring. The ring holds the two carbon bonds at nitrogen close together and connects to the rest of the molecule through that nitrogen.

1.12Two repeats at n

What ifWhat if the segment indexed by n contained two consecutive copies of its repeat unit?
Claim language“n is 0 or 1”

The segment connects the same two endpoints through two repeat units joined in series. The second unit adds one repeat unit's worth of bonds to the path between the attachment atoms.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Ex vivo testing of bovine neutrophils

A veterinary laboratory uses a small-molecule inhibitor to study granule release in neutrophils isolated from bovine blood. The assay plate contains matched wells for unstimulated cells, stimulated cells with vehicle, and stimulated cells with the inhibitor. An immunoassay measures lactoferrin in the supernatant, and a membrane integrity assay measures cell damage in parallel.

Parameter or scale variation

Timed sampling of granule release

A 96-well plate contains replicate neutrophil cultures exposed to inhibitor concentrations from 0.1 to 30 micromolar for 15 minutes before stimulation. Independent wells supply supernatant at 2, 5, 15, and 30 minutes after stimulation. Each time point includes a stimulated vehicle control and an unstimulated control, and an immunoassay measures released lactoferrin.

Combination with existing systems

Perfused neutrophil and endothelial cell culture

A two-channel microfluidic device carries an endothelial monolayer on a porous membrane between the channels. Neutrophils and the inhibitor enter the vascular channel, and a chemoattractant in the opposing channel establishes a gradient across the membrane. Microscopy counts neutrophils that cross the membrane, and immunoassays measure released granule proteins in effluent from both channels.

Inhibitor testing in perfused lung slices

A perfusion chamber holds a precision-cut lung slice on a porous support and circulates medium containing the inhibitor. Fluorescently labeled neutrophils enter the chamber with the perfusate, and matched chambers receive vehicle with the same inflammatory stimulus. Imaging quantifies neutrophil accumulation in the tissue, and effluent sampling tracks extracellular lactoferrin over time.

Automated or data-driven variant

Automated analysis of granule surface markers

A liquid handler dispenses inhibitor dilutions and stimulus into a plate of neutrophils and adds fluorescent antibodies against surface CD63 and CD66b at a fixed time after stimulation. A plate-sampling flow cytometer records antibody fluorescence and a viability dye for each cell. Software selects live single cells, normalizes each marker to the stimulated vehicle control, and fits a separate concentration-response curve for each marker.

Specific version of a part

Methoxy at the R1 position

R1 is methoxy, —OCH3, with oxygen bonded directly to the core. The group contains one alkyl carbon, and its ether oxygen serves as a hydrogen-bond acceptor.

Three fluorines on ethyl

A 2,2,2-trifluoroethyl group attaches through its methylene carbon as —CH2CF3. Three fluorine atoms occupy the terminal carbon.

Cyano on a phenyl ring

A phenyl ring serves as Cy and carries one cyano group at the carbon opposite its attachment point. The nitrile carbon bonds directly to the ring, and the carbon–nitrogen triple bond gives the substituent a linear axis.

Ethylamino group with one hydrogen

R is H and R′ is ethyl, giving —NHCH2CH3. The nitrogen bonds to the parent group, one hydrogen, and the methylene carbon of the ethyl group.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2006/0063789 A1
Published
Mar 23, 2006
Filed
Oct 29, 2002
Class
A61K 31/655
Document BUS 2009/0312341 A1
Published
Dec 17, 2009
Filed
Jun 24, 2009
Class
A61K 31/496
Claim 1
Document A
Document B
1.1R1 is selected from the group consisting of H, —NO2, —OH, —C1-C6-alkyl, —C1-C6-haloalkyl, —C1-C6-alkyl-O—(C1-C6-alkyl), —C1-C6-alkenyl, —C1-C6-alkoxyl, —NRR′, —C(O)R, C3-C8-cycloalkyl, and —C6-C10-aryl
C1-6alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; polyhaloC1-6alkylthio; R7—C(═O)—; —NHC(═O)H; —C(═O)NHNH2;
A · US 2006/0063789 A1 · ¶ 15
and wherein l, n, m, Y, and R6, R7, R8, R9, R10, R11, R12 and R13 are as defined in the following groups (A) to (C): (A) when l is 0-3; n is 0-3; m is 0 or m is 1 and Y is —C(R30)(R31)—; and the sum of l and n is 0-3: (i) R6, R7, R8, R9, R10 and R11 are independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl, alkynyl, halo, —NO2, —CN, —N(R15)(R16),
B · US 2009/0312341 A1 · ¶
1.2wherein any alkyl, alkenyl, alkoxyl, and cycloalkyl is optionally substituted with 1 to 6 halo
C2-6alkenyl substituted with one or more halogen atoms or cyano;
A · US 2006/0063789 A1 · ¶ 15
and wherein each of the alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkenyl and alkynyl groups in R, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R24, R25 and R30 are independently unsubstituted or substituted by 1 to 5 R32 groups independently selected from the group consisting of halo, alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl
B · US 2009/0312341 A1 · ¶ 36
1.3X is —NRX(R2) or C1-C6-alkyl
and wherein l, n, m, Y, and R6, R7, R8, R9, R10, R11, R12 and R13 are as defined in the following groups (A) to (C): (A) when l is 0-3; n is 0-3; m is 0 or m is 1 and Y is —C(R30)(R31)—; and the sum of l and n is 0-3: (i) R6, R7, R8, R9, R10 and R11 are independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl, alkynyl, halo, —NO2, —CN, —N(R15)(R16),
B · US 2009/0312341 A1 · ¶
1.4RX is H or C1-C6-alkyl
1.5R2 is selected from the group consisting of Het, Cy, —C(O)(Het), —C(O)(Cy), —C(O)(NH)(Het), —C(O)(NH)(Cy), —OC(O)(Het), —OC(O)(Cy), —O(Het), —O(Cy), —(C1-C6-alkyl)(Het), —(C1-C6-alkyl)(Cy), —(C1-C6-hydroxyalkyl)(Het), —(C1-C6-hydroxyalkyl)(Cy), —(C2-C6-alkenyl)(Het), —(C2-C6-alkenyl)(Cy), —(NR)(C1-C6-alkyl)(Het), —(NR)(C1-C6-alkyl)(Cy), —(NR)C(O)(Het), —(NR)C(O)(Cy), —(C3-C8-cycloalkyl)N(R)C(O)—Cy, —C1-C6-alkyl(NR)C(O)N(C6-C10-aryl)2, and —C1-C6-alkyl (optionally substituted with NRR′)
C1-6alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said groups representing R8 may optionall
A · US 2006/0063789 A1 · ¶ 15
R19 is optionally substituted alkyl, —SO2R18, —C(O)R18 or optionally substituted heteroarylalkyl, preferably alkyl, optionally substituted benzyl, benzoyl, (optionally substituted heteroaryl)alkyl, —SO2alkyl, —SO2(optionally substituted phenyl), —SO2-naphthyl, (phenyl-alkenyl)-SO2—, —SO2— (optionally substituted benzyl), —SO2— (optionally substituted heteroaryl), phenyl, —C(O)alkyl, —C(O)-(phenyl), —C(O)-heteroaryl, —C(O)N(alkyl)2, —C(O)—O-benzyl, —SO2— (optionally substitute
B · US 2009/0312341 A1 · ¶
1.6Het is a 3- to 20-membered monocyclic, bicyclic, tricyclic, or tetracyclic heterocyclic ring system wherein 1 to 6 ring members are independently selected from N, O, and S, and wherein the ring system is fully saturated, partially saturated, aromatic, or a combination thereof
R20 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle;
A · US 2006/0063789 A1 · ¶ 15
“Heterocyclyl” (or heterocycloalkyl) means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which 1-3, preferably 1 or 2 of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination.
B · US 2009/0312341 A1 · ¶ 84
1.7Cy is a 4- to 15-membered monocyclic, bicyclic, or tricyclic carbocyclic ring system that is fully saturated, partially saturated, aromatic, or a combination thereof
R20 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle;
A · US 2006/0063789 A1 · ¶ 15
1.8Het and Cy are optionally substituted with 1 to 6 substituents independently selected from the group consisting of halo, —OH, —CN, oxo, thio, —NRR′, —C1-C6-alkyl, —C1-C6-haloalkyl, —C3-C8-cycloalkyl, —(C1-C6-alkyl)(NH)0-1(C3-C8-cycloalkyl), —C6-C10-aryl, —O—C6-C10-aryl, —C(O)—C6-C10-aryl, —C(O)NH—C6-C10-aryl, —S(O)0-2—C6-C10-aryl, —(C1-C6-alkyl)-(O)0-1—(C6-C10-aryl), —C(O)NRR′, —C(O)OR, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), —C(O)(5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S)), —NR(C1-C6-alkyl)(5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), 5- to 8-membered heterocycloalkyl (wherein 1-4 ring members are independently selected from N, O, and S) optionally fused to C6-C10-aryl, —(C1-C6-alkyl)(CONH)0-1(5- to 8-membered heterocycloalkyl (wherein 1-4 ring members are independently selected from N, O, and S))
and wherein each of the alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkenyl and alkynyl groups in R, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R24, R25 and R30 are independently unsubstituted or substituted by 1 to 5 R32 groups independently selected from the group consisting of halo, alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl
B · US 2009/0312341 A1 · ¶ 36
1.9wherein any alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl moiety is substituted by 1 to 3 substituents selected from the group consisting of halo, —CN, oxo, —OH, —NRR′, —C1-C6-alkyl, —C1-C6-haloalkyl, and —(C1-C6-alkyl)(C6-C10-aryl)
Y3 or Y4 each independently are a direct bond, C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl; n is 1 or 2; m is 1 or 2; p is 1 or 2; r is 1 to 5; s is 1 to 3; aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl and polyhaloC1-6alkyloxy; provided that —X—R2 and/or R3 is other than hydrogen; and provided that the following compounds
A · US 2006/0063789 A1 · ¶ 15
and wherein each of the alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkenyl and alkynyl groups in R, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R24, R25 and R30 are independently unsubstituted or substituted by 1 to 5 R32 groups independently selected from the group consisting of halo, alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl
B · US 2009/0312341 A1 · ¶ 36
1.10each instance of R and R′ is independently selected from H and C1-C6-alkyl
C1-6alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; polyhaloC1-6alkylthio;
A · US 2006/0063789 A1 · ¶ 15
Especially preferred R groups in structure (1a) are alkyl, alkoxyalkyl and cycloalkylalkyl; especially preferred R14 groups in structure (1a) are hydrogen and alkyl, particularly wherein one R14 is hydrogen and the other is hydrogen or alkyl.
B · US 2009/0312341 A1 · ¶
1.11or R and R′, together with the nitrogen atom to which they are bound, form a 5- to 8-membered heterocycloalkyl (wherein 1-3 additional ring members are independently selected from N, O, and S)
R5 and R6 each independently are hydrogen, R8, —Y1—NR9—Y2—NR10R11, —Y1—NR9—Y1—R8, —Y1—NR9R10, or R5 and R6 may together with the nitrogen to which they are attached form a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle, each of said heterocycles may optionally be substituted with one or more substituents selected from R12, R13 and R14, or each of said heterocycles may optionally be fused with a ben
A · US 2006/0063789 A1 · ¶ 15
or R24 and R25 together with the nitrogen to which they are attached, form a 3-7 membered heterocycloalkyl ring;
B · US 2009/0312341 A1 · ¶ 33
1.12n is 0 or 1 wherein the compound is not:
Y3 or Y4 each independently are a direct bond, C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl; n is 1 or 2; m is 1 or 2; p is 1 or 2; r is 1 to 5; s is 1 to 3; aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl and polyhaloC1-6alkyloxy; provided that —X—R2 and/or R3 is other than hydrogen; and provided that the following compounds
A · US 2006/0063789 A1 · ¶ 15
In another embodiment, preferred are compounds of formula I, definition (A), wherein m is zero; n is 1 and the sum of n and l is 1 or 2;
B · US 2009/0312341 A1 · ¶ 62

An empty cell means only that no passage was reproduced there.

Statements in these documents
The present invention concerns a novel group of compounds, their use as a medicine, their use for the manufacture of a medicament for the treatment of diseases mediated through glycogen synthase kinase 3, in particular glycogen synthase kinase 3β; processes for their preparation and pharmaceutical compositions comprising them.
A · US 2006/0063789 A1 · ¶ 1
Therefore there is an unmet medical need for AD treatments that halt disease progression.
B · US 2009/0312341 A1 · ¶ 3
Thus inhibition of BACE-1 is a therapeutic approach to the treatment of AD and other cognitive and neurodegenerative diseases caused by Aβ plaque deposition.
B · US 2009/0312341 A1 · ¶ 7
Cite aspatent.fyi, US 2026/0355189 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355189/, SHA-256 b46a76b446fbdc2e7443c9df136d805c9e3f7cd912a7694c0ae5de7eb59d7570
First published
Permanent addresshttps://patent.fyi/US20260355189/
Content fingerprint (SHA-256)b46a76b446fbdc2e7443c9df136d805c9e3f7cd912a7694c0ae5de7eb59d7570
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi